Mice Study on [18F]Flutemetamol and Myelin Quantification
In a study with 10 male C57BL/6 mice, cuprizone treatment led to significant body weight loss and demyelination in the corpus callosum verified by MRI. While [18F]Flutemetamol PET showed low brain retention and rapid tracer washout, it failed to detect myelin loss effectively due to poor sensitivity and quantitative robustness.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
These findings suggest that while cuprizone can induce demyelination, the ability of [18F]Flutemetamol PET to quantify myelin loss in vivo is severely limited, indicating a need for better imaging techniques.
What this does not prove
The study did not demonstrate that [18F]Flutemetamol PET can reliably assess myelin loss, and negative results could arise from tracer and methodological limitations.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 10 · basis not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-05
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Male C57BL/6 mice fed 0.3% cuprizone for five weeks
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceLow Uptake of [18F]Flutemetamol in the Mouse Brain Prevents Non-invasive Quantification of Myelin. ↗DOI: 10.1021/acs.molpharmaceut.6c00470
Supporting passages (14)
subjectsAnimal
speciesMice
sample size10
randomizedNo
publication date2026-10-05
intervention[18F]Flutemetamol
primary endpointTitle: Low Uptake of [18F]Flutemetamol in the Mouse Brain Prevents Non-invasive Quantification of Myelin.
follow upMale C57BL/6 mice were fed 0.3% cuprizone for five weeks (n = 5) or control chow (n = 5) and subsequently underwent a 90 min dynamic [18F]Flutemetamol PET/CT scan with a retest scan two days later.
findingsCuprizone treatment induced significant body weight loss and robust region-specific demyelination of the corpus callosum, confirmed by reduced myelin marker expression, increased astroglial and microglial activation, and corresponding MRI changes.
limitations[18F]Flutemetamol PET/CT did not provide sufficient sensitivity or quantitative robustness to detect myelin loss in vivo.
populationMale C57BL/6 mice were fed 0.3% cuprizone for five weeks (n = 5) or control chow (n = 5) and subsequently underwent a 90 min dynamic [18F]Flutemetamol PET/CT scan with a retest scan two days later.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Animals; Myelin Sheath; Benzothiazoles; Male; Mice; Mice, Inbred C57BL; Aniline Compounds; Demyelinating Diseases; Cuprizone; Brain; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Disease Models, Animal; Magnetic Resonance Imaging
human efficacyAnimal
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.